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http://www.jneurodevdisorders.com/content/6/1/27RESEARCH Open AccessGenomic studies in fragile X premutation carriers
Reymundo Lozano1,2*, Randi J Hagerman1,2, Michael Duyzend3, Dejan B Budimirovic4, Evan E Eichler3,5
and Flora Tassone1,6Abstract
Background: The FMR1 premutation is defined as having 55 to 200 CGG repeats in the 5′ untranslated region of
the fragile X mental retardation 1 gene (FMR1). The clinical involvement has been well characterized for fragile
X-associated tremor/ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI). The
behavior/psychiatric and other neurological manifestations remain to be specified as well as the molecular
mechanisms that will explain the phenotypic variability observed in individuals with the FMR1 premutation.
Methods: Here we describe a small pilot study of copy number variants (CNVs) in 56 participants with a
premutation ranging from 55 to 192 repeats. The participants were divided into four different clinical groups for the
analysis: those with behavioral problems but no autism spectrum disorder (ASD); those with ASD but without
neurological problems; those with ASD and neurological problems including seizures; and those with neurological
problems without ASD.
Results: We found 12 rare CNVs (eight duplications and four deletions) in 11 cases (19.6%) that were not found in
approximately 8,000 controls. Three of them were at 10q26 and two at Xp22.3, with small areas of overlap. The
CNVs were more commonly identified in individuals with neurological involvement and ASD.
Conclusions: The frequencies were not statistically significant across the groups. There were no significant
differences in the psychometric and behavior scores among all groups. Further studies are necessary to determine
the frequency of second genetic hits in individuals with the FMR1 premutation; however, these preliminary results
suggest that genomic studies can be useful in understanding the molecular etiology of clinical involvement in
premutation carriers with ASD and neurological involvement.
Keywords: Premutation, FMR1 gene, Autism, Second hit, ASD, Neurodevelopmental disorders, Neurological disordersBackground
As the FMR1 premutation (55 to 200 CGG repeats) is
common in the general population (1 in 130-259 females
and 1 in 450-813 males) [1], the phenotypic manifesta-
tions of carriers may impact more than 1 million indi-
viduals in the US alone. Approximately 20% of female
carriers have fragile X-associated primary ovarian insuffi-
ciency (FXPOI) [2], and 40% of male carriers and 8 to
16% of female carriers have fragile X-associated tremor/
ataxia syndrome (FXTAS) [3,4].
In general, developmental problems in childhood occur
in approximately 15 to 20% of premutation carriers.
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showed that 8% have a diagnosis of autism spectrum dis-
order (ASD) and 30% of attention deficit hyperactivity dis-
order (ADHD) [5]. Approximately 70% of boys with the
premutation who present clinically to a center with autism
diagnostic testing have ASD, whereas 60% have ADHD
and 20% have intellectual disability (ID) [5].
There are many reasons for the variability of clinical in-
volvement in carriers. As the number of CGG repeats
increases, the level of the encoded product of the FMR1
gene (fragile X mental retardation protein; FMRP) de-
creases [6,7]. The low levels of FMRP are likely associated
with both lower IQ and more emotional and behavioral
problems [8,9]. In addition, the level of FMR1 mRNA in-
creases as the CGG repeat number increases [10] leading
to RNA toxicity involving sequestration of important pro-
teins for neuronal function, such as Sam 68, DROSHALtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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events include upregulation of heat shock proteins [12]),
dysregulation of Lamin A/C [13], deterioration of mito-
chondrial function [14,15] and the formation of potential
toxic polypeptides [16]. Neuronal cell cultures of the pre-
mutation CGG mouse (knock-in; KI) showed altered den-
dritic branching, early death [12], enhanced spikes [17]
and mitochondrial dysfunction [18]. Cunningham and col-
laborators [19] have also demonstrated abnormalities in
neuronal migration during development in the premuta-
tion CGG mouse. This led us to hypothesize that patients
with the FMR1 premutation may be particularly suscep-
tible to an FMR1-based ‘double hit’, which in addition to a
second genetic hit will cause exacerbation of the clinical
phenotype in carriers.
Copy number variants (CNVs), one of the sources
leading to genetic variability in humans, can be respon-
sible for Mendelian or sporadic traits but can also be as-
sociated with complex disorders. Indeed several studies
have suggested that rare, large events can significantly
contribute to the risk for a number of human disorders
including ASD and ID [20-22]. Thus, we have investi-
gated the role of genomic changes by assessing CNVs in
premutation carriers to better understand the relation-
ship with the observed clinical variability.
Methods
Study subjects
Subjects with a premutation in FMR1 were recruited
through the Fragile X Treatment and Research Center at
the UC Davis MIND Institute (Sacramento, CA, USA)
according to a UC Davis Institutional Review BoardFigure 1 Diagram of the distribution of the CNVs among participants
number variant.(IRB) approved protocol and all signed consent for this
study. All statistical analyses were completed using
SPSS Statistics Version 21 (IBM Corporation, Armonk,
NY, USA). Comparisons between groups were conducted
using t-tests and chi-square tests, with a P value of less
than 0.05 considered significant. A total of 56 patients
with the premutation were recruited, four were females
and 52 were males, and the mean age was 17.7 years old
(SD 13.2 years). Of the total 56 patients: 19 had ASD
(Group 1); 20 had neither ASD nor neurological problems
but may have had ADHD, anxiety or other behavioral
problems (Group 2); nine had ASD and neurological prob-
lems (Group 3); and eight had only neurological problems
(Group 4) (Figure 1). The diagnosis of ASD was given
according to the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) [23] and Inter-
national Statistical Classification of Diseases and Related
Health Problems, 10th revision (ICD-10) [24] criteria.
Neurological problems included seizures, autonomic dys-
function, tremors, ataxia, weakness or paralysis. While
most of the symptomatic participants were probands,
most of the participants who did not have a diagnosis of
ASD or neurological problems were non-probands, and
only a few of these individuals were probands due to be-
havior problems (anxiety, ADHD and depression).
Molecular measures
CGG sizing
Genomic DNA was extracted from 3 to 5 ml of blood
using standard procedure (Qiagen, Valencia, CA, USA).
CGG repeat sizing was performed by PCR and Southern
blot analysis as previously described [25,26].in the four groups. ASD, autism spectrum disorder; CNV, copy
Lozano et al. Journal of Neurodevelopmental Disorders 2014, 6:27 Page 3 of 8
http://www.jneurodevdisorders.com/content/6/1/27Copy number variants (CNVs)
Rare CNVs are defined as deletions and duplications oc-
curring at a frequency <0.1% in the general population
(8,328 controls). We utilized the genomic architecture of
the human genome to identify regions of rare, recurrent
CNVs. Segmental duplications are large blocks of se-
quences (>10 Kb) with high sequence identity (>95%) and
interspersed in the human genome [27,28]. Segmental du-
plications, due to their high sequence identity, can there-
fore form substrates for unequal crossover during meiosis
resulting in deletions or duplications of the intervening re-
gion, termed genomic hotspots [27,29]. We utilized a pre-
viously designed custom 12-plex NimbleGen array with a
total of 135,000 probes targeted to genomic hotspots for
CNV detection [30]. The hotspot array consists of a high
density of probes (approximately 2.6 Kb) targeting 107
genomic hotspot regions (approximately 251 Kb) and a
probe spacing of approximately 36 Kb in the genomic
backbone. Array hybridization experiments and analysis
were performed as described previously [21]. All signal in-
tensities from the CGH experiments were loaded onto a
UCSC Genome Browser mirror (Santa Cruz, CA, USA)
and manually visualized. We also called CNVs using a hid-
den Markov model (HMM)-based segmentation algorithm
from the normalized signal intensity data. This algorithm
generates a normal distribution based on the probe signal
intensities for each chromosome and generates z-scores
(based on a 2 SD Gaussian model) for sets of probes that
are either deleted or duplicated within that chromosome
[30]. CNV calls were refined by applying the following
filters: z-score < |1.5|, probes <10, >50% overlap with
segmental duplications and length <50 Kb. We observed
how many events had >50% reciprocal overlap with
8,328 controls [31].
Cognitive and behavioral measures
The Autism Diagnostic Observation Schedule (ADOS) [32]
and Autism Diagnostic Interview-Revised (ADI-R) [33]
were used to diagnose ASD. Behavioral scales, the Vineland
Adaptive Behavior Scales, 2nd edition (VABS-II) [34], and
the Swanson, Nolan and Pelham, version IV (SNAP-IV)
scale [35] for ADHD were also administered. The neuro-
psychological/neuropsychiatric assessments included stan-
dardized IQ tests, including different assessment methods:
Stanford-Binet Intelligence Scales, 5th edition (SB-5)
[36]; and Wechsler Adult Intelligence Scales (WAIS-III
or WAIS-IV) [37,38].
Results
A premutation was confirmed in all individuals and the
CGG repeat size ranged from 55 to 192 repeats. Of the
56 subjects included in this study, 11 (19.6%) were found
to have rare CNVs (average size = 508 Kb; Table 1): three
of these were in Group 1 (ASD and no neurologicaldisorders); three in Group 2 (no ASD and no neurological
disorders); one in Group 3 (ASD with neurological dis-
orders); and four in Group 4 (no ASD with neurological
disorders) (Figure 1). The frequency of CNVs was not sig-
nificantly higher in carriers with neurological signs com-
pared to the premutation carriers without neurological
disorders (5/17, 29.4% versus 6/39, 15.4%, χ2, df 1, P =
0.196) or among individuals with neurological disorders
with and without ASD (1/9, 11.1% versus 4/8, 50%, χ2, df 1,
P = 0.570); however, a trend was observed towards partici-
pants with neurological signs. From the 29 individuals with
ASD, regardless of the presence of neurological disorders,
four had a CNV (7.1%); and from the 27 individuals with-
out ASD, seven had a CNV (12.5%, χ2, df 1, P = 0.211). A
McNemar test (binominal distribution) showed a signifi-
cant difference between the percentage of CNVs in neuro-
logically affected individuals with and without ASD (n = 56,
P = 0.035).
The CNVs were eight duplications and four deletions,
ranging from 175 Kb to 1.6 Mb; one individual had both a
duplication (1.6 Mb) and a deletion (347 Kb). Five duplica-
tions ranging in size from 160 Kb to 1.6 Mb were found in
patients with neurological problems. Interestingly, three
of them were at 10q26, two of them overlapping (coordi-
nates: 134,543,728 to 134,941,539) with duplication of genes
C10orf933, G-protein-coupled receptor 123 (GPR123),
KNDC1, undifferentiated embryonic cell transcription fac-
tor 1 (UTF1), Vent homeobox (VENTX), microRNA 202
(MIR202) and A disintegrin and metalloproteinase 8
(ADAM8). In addition, two individuals carried a duplica-
tion on Xp22.3 with a small area of overlapping (6,442,757
to 6,907,093), which included the VCX3 gene. Only five of
the 11 individuals had follow-up studies to determine if
the CNVs were familial or de novo; three of them were
followed by parental studies and all three were found to be
inherited from asymptomatic parents (two maternal and
one paternal); in the other two participants, parents were
not available. We followed their offspring and the CNVs
were not inherited to their asymptomatic children.
Taking in account all events (rare and common) after
accurate filtering, total CNV burden analysis showed a sig-
nificant enrichment of events >325 Kb was observed in
premutation cases compared to controls (P = 2.274e-07).
Analysis of the psychometric assessments of all partici-
pants showed a mean full scale (FS) IQ of 83.20 (SD
23.0916) and ADOS total score of 4.45 (SD 6.53). Individ-
uals with the premutation and a CNV had an ADOS mean
score of 7.1 (SD 3.93) and FS IQ of 88.14 (SD 20.96). The
participants without a CNV had an ADOS mean of 8.15
(SD 5.92) and FS IQ of 81.96 (SD 23.79), and these results
were not statistically significant (ADOS, P = 0.6760 and IQ,
P = 0.7218). Social Communication Questionnaire (SCQ)
total score among individuals with a CNV had a mean of
13.88 (SD 9.5235) and among the individuals without a
Table 1 Demographic, clinical and molecular measures
Case Gender Age(years)
CGG
repeat size
FMR1
mRNA Region Start End Size Inheritance
Controls
n = 8,328
(50% reciprocal)
Gene(s)
Groupa
Other clinical information
1 M 12 64 2.19 (0.3) Del 11q13.3 70,077,400 70,614,279 536 Kb Unknown 0 SHANK2 1 Significant cognitive deficits,
anxiety, tactile sensitivity,
hyperactivity and
perseveration
2 M 15 58 1.57 (0.06) Del 6q26 162,565,963 162,748,669 182 Kb Familial/
maternal
0 PARK2 1 Anxiety, hyperactivity, ID,
tactile defensiveness,
perseveration and aggression
3 M 5 81 2.41 (0.16) Del 2q21.3 135,591,912 135,966,218 374 Kb Familial/
paternal
0 RAB3GAP1,
ZRANB3
3 Severe autism, ADHD,
obsessive behavior and EEG
with generalized polyspikes
during sleepDup Xp22.31 6,442,757 8,115,638 1.67 Mb Unknown 0 VCX3A, HDHD1,
STS, VCX, PNPLA4,
MIR651, VCX2
4 M 9 66 1.95 (0.23) Dup Xp22.31 6,404,592 6,907,093 502 Kb Unknown 0 VCX3A 2 Anxiety, learning problems,
trichotillomania, phobias and
psychosis
5 F 69 20, 80 2.11 (0.2) Dup 10q26.3 134,492,316 134,941,539 449 Kb Not inherited
to daughter
0 C10orf93, GPR123,
KNDC1, UTF1,
VENTX, MIR202,
ADAM8
4 Severe autonomic
dysfunction, tremor, ataxia
and memory problems
6 F 35 29, 106 3.32 (0.44) Dup 10q26.3 134,543,728 134,955,025 411 Kb Not inherited
to son
0 C10orf93, GPR123,
KNDC1, UTF1,
VENTX, MIR202,
ADAM8, TUBGCP2
4 Severe autonomic
dysfunction, ataxia, tremor,
orthostatic hypertension and
migraines
7 M 14 192 5.02 (0.49) Dup 6p22.3 17,977,030 18,137,572 160 Kb Unknown 0 KIF13A 1 Significant sensory
integration issues, suicidal
threats, hearing voices and
frequent tantrums
8 M 7 99 2.98 (0.22) Dup 10q26.2 128,750,641 129,507,857 757 Kb Unknown 0 DOCK1, FAM196A,
NPS, FOXI2
4 OCD and severe autonomic
function
9 M 6 80 2.14 (0.1) Dup 13q12.12 24,060,479 24,236,403 175 Kb Familial/
maternal
0 LOC374491,
ATP12A, RNF17
2 Severe behavior problems
and tantrums
10 M 6 56 1.77 (0.1) Del 21q21.2 23,370,733 23,780,822 410 Kb Unknown 0 None 2 Anxiety, obsessive
compulsive, tactile aversion
and hyperarousal
11 F 31 29, 102 2.91 (0.03) Dup 3q27.1 184,311,092 184,784,473 473 Kb Unknown 0 LAMP3, MCF2L2,
B3GNT5, KLHL6
4 Depression
aGroup 1, ASD and no neurological disorders; Group 2, no ASD and no neurological disorders; Group 3, ASD with neurological disorders; and Group 4, no ASD with neurological disorders. ADHD, attention deficit
hyperactivity disorder; ASD, autism spectrum disorder; EEG, electroencephalography; F, female; M, male; OCD, obsessive compulsive disorder.
Lozano
et
al.Journalof
N
eurodevelopm
entalD
isorders
2014,6:27
Page
4
of
8
http://w
w
w
.jneurodevdisorders.com
/content/6/1/27
Lozano et al. Journal of Neurodevelopmental Disorders 2014, 6:27 Page 5 of 8
http://www.jneurodevdisorders.com/content/6/1/27CNV had a mean of 11.5 (SD 9.8290), with no significant
difference (P = 0.6398).
ADHD was found in 28/56 (50%) of individuals, of
whom five had a CNV compared to 23/28 without a CNV.
There were no significant differences in the CGG allele
size between the group without a CNV (mean 90.95, SD
38.93) compared to those with a CNV (mean 84.85, SD
47.64, P = 0.4302).
We briefly describe six patients with genomic changes
in more detail.
Case 1
The patient was an adopted 12-year-old male with a pre-
mutation allele of 64 CGG repeats whose biological par-
ents were not available. The patient had a diagnosis of
ASD and severe behavior problems (Group 2). IQ was
not available. CNV analysis showed the presence of a
536 Kb deletion in 11q13.3 involving the SHANK2 gene,
which encodes for a multi-domain molecular scaffolding
protein enriched in neuronal synapses. SHANK2 dele-
tions have been associated with autism [39]. Moreover, it
has been recently reported that the SHANK2 mutant
mouse recapitulates many of the behavioral phenotypes
that are typical of ASD [40]. In this patient, the add-
itional effects of the SHANK2 deletion and the premuta-
tion may have caused ASD, but it is also a possibility
that the deletion alone was responsible for the ASD.
Case 2
The patient was a 15-year-old male with premutation of
58 CGG repeats. The patient had a diagnosis of anxiety,
autism, ID (IQ = 54) and ADHD. The patient’s problem
behaviors included frequent tantrums associated with
aggressive episodes and hand flapping when excited or
anxious. The patient’s physical examination was remark-
able for broad knuckles, long tapered fingers and in-
creased muscular tone. The patient was found to have a
maternally inherited 180 Kb deletion in 6q26 that dis-
rupted the PARK2 gene. CNVs including the PARK2
gene region have previously been reported in autism
[41,42]. The PARK2 gene encodes for the E3 ubiquitin-
protein ligase, parkin, widely expressed in neuronal cells
[43]. Parkin targets proteins for degradation in the cell.
UBE3A, a protein from the same family, is associated
with both autism and Angelman syndrome. PARK2 has
also been associated with mitochondrial function, par-
ticularly in protecting mitochondrial genomic integrity
from oxidative stress [44]. Mitochondrial function is
altered in subjects with autism [45], supporting parkin’s
potential role in the pathophysiology of autism. The
PARK2 gene mutation is likely to have added to the
baseline mitochondrial dysfunction in the premutation
leading to ASD and ID. However, as PARK2 variants
have also been observed in individuals for the generalpopulation, the assessment of their pathogenicity can be
quite complex.
Case 3 and 4
These two patients were both males of 5 and 9 years of
age (Table 1). Patient 3 had a premutation of 81 CGG
repeats, duplication on Xp22.3 and a deletion on 2q21.3.
This patient was diagnosed with autism, seizures and se-
vere behavior problems. Case 4 had a premutation of 66
CGG repeats and duplication on Xp22.3. This patient
was diagnosed with severe behavior problems but not
with ASD. The duplication observed in these two cases
had only one duplicated gene in common (VCX3A). The
parents were not available for parental studies. The dele-
tion of the VCX3A gene was initially reported to be as-
sociated with ID [46], but was found to be not sufficient
to result in ID [47]. The duplication of these genes in
addition to the premutation may have caused the more
severe observed behavior problems.
Case 5 and 6
Cases 5 and 6 were premutation carrier females (alleles
with 80 and 106 CGG repeats, respectively, (Table 1),
and were found to have overlapping duplicated regions
of 449Kb and 411 Kb, respectively, at 10q26.3. They had
similar clinical presentation including seizures, tremor,
ataxia and autonomic dysfunction, which are common
features of the FXTAS phenotype. While deletions of
10q26 have been associated with autism [48], the dupli-
cation on 10q26 has not been described to be pathogenic
nor a benign CNV and was observed in only three cases
of our CNV controls (3/8,328). It is also intriguing that
this duplication was found in two individuals (Group 4)
in this small cohort presenting with similar neurological
phenotypes. These duplications were not inherited by
their offspring. Little is known about the genes in the
duplicated region; thus, further studies are necessary
and may provide relevant information on these genes
whose function may be relevant to neurodegenerative
disorders including FXTAS.
Discussion
CNVs detected in recent studies of individuals with ASD
have been shown to disrupt a number of genes that are
collectively the cause of phenotypic variations [49]. The
requirement of multiple genes for disease expression or
multiple domains of expression of a largely monogenic dis-
order are manifestations of incomplete penetrance of any
single gene; thus, mutations in multiple genes are required
for full penetrance and for a more severe clinical pheno-
type [50]. Mutations within the FMR1 gene can present
with a variety of clinical phenotypes. For example, the pre-
mutation presents with the well characterized neurodegen-
erative disorder, FXTAS, and with FXPOI; however, it is
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these abnormalities are believed to be associated with
RNA toxicity [51]. Remarkably, the neurological and neu-
rodevelopmental disorders associated with the premuta-
tion have incomplete penetrance and variable expression
even among families. This phenotypic variability suggests
the participation of other ‘background’ modifier genes that
when disrupted will cause additive effects.
In addition, since the FMRP regulates the function of
several genes, the premutation in combination with
other genetic hits can cause other neurological and neu-
rodegenerative disorders (Figure 2).
Along with the rapid genomic technological advances
in the past few years, conceptual and technological chal-
lenges have emerged. It is important to clarify molecular
techniques and their limitations, particularly in the clin-
ical realm.
Microarrays and whole exome/genome sequencing
cannot be compared as they involve different molecular
techniques and are meant to detect different genetic ab-
normalities (CNVs versus single base pair changes). A
second hit can also include a single base change, for ex-
ample, in one of the studied participants, a non-verbal
22-year-old male with a premutation of 68 CGG repeats
presented with autism, severe intellectual disability, sei-
zures, macrocephaly and other mild facial dysmorphic
features. While our CNV analysis did not detect the
presence of a deletion or duplication, whole exome se-
quencing showed a de novo variant of uncertain clinicalFigure 2 Diagram of the clinical involvement in premutation carriers
hit that in addition to additional second hits may result in the variability of
autism spectrum disorder; FXPOI, fragile X-associated primary ovarian insuffsignificance (c.4010_4034del21) in the PTCH1 (patched
Drosophila homolog) gene, which encodes for a 18 kDa
histone H1-like protein, a transmembrane protein con-
taining a patched-related domain with 12 transmem-
brane helices. A mutation within this gene has been
observed in a child with ASD and Gorlin syndrome
[52]; therefore, in this case the premutation and the de
novo variant could have led to a more severe phenotype.Conclusion
To our knowledge this is the first study that shows rare
CNVs in carriers of the FMR1 premutation. A significant
increase in the number of CNVs, specifically duplications,
even after removal of rare and perhaps pathogenic events,
has been found to be associated with autism [53]. The fre-
quency of CNVs observed in the premutation with ASD is
comparable to the rates seen in autism alone. Follow-up
studies with an increased sample size are necessary to
confirm and clarify these findings. Although preliminary,
our overall results show the significant yield of genomic
changes in individuals with the premutation presenting
with neurological/neurodevelopmental disorders, includ-
ing ASD. Future studies, including those that integrate a
holistic molecular understanding of the interplay and con-
sequences of FMR1 genotype, mRNA and FMRP levels, in
the context of detailed patient phenotypes, should further
advance our understanding of the mechanism(s) under-
lying variable expression in premutation carriers.and potential players. The FMR1 premutation may represent a first
the phenotype. ADHD, attention deficit hyperactivity disorder; ASD,
iciency; FXTAS, fragile X-associated tremor/ataxia syndrome.
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Subjects were recruited through the Fragile X Treatment
and Research Center at the UC Davis MIND Institute
(Sacramento, CA, USA) according to a UC Davis Institu-
tional Review Board (IRB) approved protocol and all par-
ticipants signed a consent for this study. Cases reported
in the manuscript were consented for the report to be
published.
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